Compare Amylx Pharmaceuticals Inc (AMLX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs BIO-TECHNE Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while BIO-TECHNE Corp trades at $71.44 (market cap $11.11B). The key difference: BIO-TECHNE Corp is far larger — about 5.6× Amylx Pharmaceuticals Inc's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | TECH | |
|---|---|---|
Market Cap | $1.98B | $11.11B |
Sector | Health | Health |
52-Week High | $18.70 | $71.38 |
52-Week Low | $7.64 | $43.31 |
Enterprise Value | $1.70B | $11.19B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Bio-Techne (TECH) trades at $71.30, up 0.21% today, near the $73.00 acquisition offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with moving averages supporting upside, while fundamentals reveal high valuation multiples (P/E 101.84) amid declining net margins (6.01% in 2025). Recent earnings were mixed with one beat and two misses in the last four quarters. Cash flow improved in 2026 projections, and the balance sheet remains solid with $152.86M cash.
The pending acquisition at $73.00 per share limits near-term upside but provides a floor. Risks include shareholder litigation questioning the deal's fairness and execution volatility. Analyst consensus is evenly split between Buy and Hold, with the price target slightly below current levels. The primary opportunity is the acquisition premium, while fundamental weakness in profitability poses a risk if the deal falters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
